NCT07128797View on ClinicalTrials.gov

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions
NAFLD (Non-alcoholic Fatty Liver Disease)NASH (Nonalcoholic Steatohepatitis)
Interventions
DRUG

B1344

Subcutaneous injection

OTHER

Placebo

Subcutaneous injection

Trial Locations (5)

Unknown

RECRUITING

Beijing Tsinghua Changgung Hospital (BTCH) affiliated to Tsinghua University, Beijing

NOT_YET_RECRUITING

Nanfang Hospital, Southern Medical University, Guangzhou

NOT_YET_RECRUITING

Sinopharm Tongmei General Hospital, Datong

NOT_YET_RECRUITING

The First Affiliated Hospital to Nankai University, Tianjin

NOT_YET_RECRUITING

The First Affiliated Hospital to Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

Tasly Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT07128797 - a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD） | Biotech Hunter | Biotech Hunter